Dr. John Cush RheumNow
4 years 6 months ago
Study of 155 adult patients (PsA 61/AS 94) looked at labs & CV risk factors; found IL-18 elevated in peripheral PsA more than axial PsA & AS. Elevations were higher in PsA pts w/ ischemic heart disease correlated w/ atherogenic index & TG levels https://t.co/PQ3fBi8Qdo https://t.co/mewrcwhi4o
Dr. John Cush RheumNow
4 years 6 months ago
Another Kind of COVID Discussion
Another kind of COVID (vaccination) discussion - kindness and respect for the patient
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/XkUkqQ1Vli https://t.co/lrPd6jBMjt
Dr. John Cush RheumNow
4 years 6 months ago
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
https://t.co/nUrAikqyPS https://t.co/CfmyB7Wwb6
Dr. John Cush RheumNow
4 years 6 months ago
Download this week’s podcast titled “When Less (Drug) is More (Activity) “
https://t.co/omdC3fElsb https://t.co/Hva4h9yEa9
Dr. John Cush RheumNow
4 years 6 months ago
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis
The ACR has updated its clinical guidelines for the management of JIA, with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA.
https://t.co/eKv8qubl1v https://t.co/xLBMccCYex
Gout is common but disproportionately affects certain groups (e.g., the elderly, Pacific Islander, Blacks). Ethnic links to gouts were also shown to be linked to modifiable behavioral factors and such information maybe useful in managing gout patients.
Dr. John Cush RheumNow
4 years 6 months ago
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Undifferentiated arthritis (UA) is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach.
While there are criteria for UA, it is largely a diagnosis of exclusion. Moreover, there are few well controlled trials on DMARD efficacy in UA are absent.
Dr. John Cush RheumNow
4 years 6 months ago
Drug Survival Differences in RA, PsA, SpA and PsO
https://t.co/aBRhTbVmCM https://t.co/ZDGiKlowoV
Dr. John Cush RheumNow
4 years 6 months ago
Rheumatoid Arthritis and Eosinophilia
Considerations when eosinophilia is seen in RA patients.
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/2FszCiTLgf https://t.co/07uZT2heW3
Dr. John Cush RheumNow
4 years 6 months ago
New Download Available!
Autoimmune Disease in the USA
https://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6
Dr. John Cush RheumNow
4 years 6 months ago
2021 Top Articles from Arthritis & Rheumatology
https://t.co/nxKWrkdGX3 https://t.co/iZx5MOUyA7
Dr. John Cush RheumNow
4 years 6 months ago
CORVITAS RA registry shows poor biologic responses in Severe obesity (BMI >35) & underweight (<18.5) w/ no diff between 2891 TNFi vs 3010 non-TNFi users. Severe obesity lower odds of LDA, MCID, CDAI ~10-20% UnderWt ~50-70% https://t.co/iMvlyo4UKx https://t.co/JTQ6aRVTpH
Dr. John Cush RheumNow
4 years 6 months ago
ICYMI: Spondyloarthritis in Early Crohn's Disease
Analysis of a German Crohn's disease cohort finds that in patients with early CD, SpA was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD.
https://t.co/ExAHSCw5v2 https://t.co/UDZHbg9ySY

